Check out our wide range of fillers and injectables.
No products were found matching your selection.
Monovisc is an orthopedic injectable composed of non-animal sodium hyaluronate that is used to relieve pain in patients afflicted with knee osteoarthritis. This product is manufactured by Anika Therapeutics.
Symptoms of pain and swelling associated with knee osteoarthritis in patients who have responded
inadequately to first-line treatments like pain medications and physical therapy.
The ingredients of Monovisc provide patients’ joints with the mechanical support they need and additional joint lubrication to reduce the pain associated with osteoarthritis.
Monovisc assumes the form of a viscous gel with physical properties similar to the healthy synovial fluid found in the articular joint. This product is injected to restore the natural rheological environment of the joint, resulting in reduced joint damage, lowered inflammation and the relief of symptoms.
This single-dose treatment ensures that the patient gains all the benefits of therapy in one session. The risk of infection and other procedure-related side effects is also lowered with fewer injections.
Treatment with Monovisc is ideal for patients who have tried analgesic treatments and exercise to improve their condition but found these modalities inadequate. It can be combined with other osteoarthritis treatments to supplement the effects.
Additionally, the hyaluronic acid that Monovisc is composed of is of non-animal origin, which aids in reducing hypersensitivity reactions.
The hyaluronic acid in this product is modified to give it the optimal biomechanical properties required to treat osteoarthritis effectively and to ensure long-lasting results (up to 6 months).
Monovisc is safe for use and is generally well-tolerated in patients suffering from osteoarthritis. It can be used together with other osteoarthritis treatments.
That being said, certain groups of patients should be excluded from Monovisc treatment, such as patients with known allergy to any of the components of Monovisc, active inflammation or infection at the intended injection site, bleeding disorders, who are receiving anticoagulant therapy, who are prone to keloid formation or hypertrophic scarring, who are pregnant or breastfeeding, and children under 18 years of age.
The Monovisc injection procedure does not result in any downtime, and patients can resume their daily activities right after the treatment.
